ProjectA Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per…
Basic data
Title:
A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE-119)
Duration:
16/10/2015 to 15/10/2018
Abstract / short description:
A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE-119)
Keywords:
clinical trial
klinische Studie
Involved staff
Managers
Faculty of Medicine
University of Tübingen
University of Tübingen
Cluster of Excellence: Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
Centers or interfaculty scientific institutions
Centers or interfaculty scientific institutions
Contact persons
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Faculty of Medicine
University of Tübingen
University of Tübingen
Cluster of Excellence: Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
Centers or interfaculty scientific institutions
Centers or interfaculty scientific institutions
Local organizational units
Department of Diagnostic and Interventional Radiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine